Complete side effect profiles for semaglutide, tirzepatide, and retatrutide — with clinical trial frequency data, management strategies, and a head-to-head comparison across all three compounds.
GLP-1 side effects are primarily gastrointestinal and most pronounced during dose escalation. They are transient — typically resolving within 8–12 weeks. Serious side effects (pancreatitis, thyroid effects) are rare. The most effective mitigation strategy is slow titration combined with dietary adjustments.
| Side Effect | Frequency | Severity | Management | Resolves? |
|---|---|---|---|---|
| Nausea | Very common (>10%) | Mild–Moderate | Take with food, avoid fatty meals, dose in evening | Usually resolves by week 8–12 |
| Vomiting | Common (1–10%) | Mild–Moderate | Slow titration, small frequent meals, stay hydrated | Usually resolves with dose stabilization |
| Diarrhea | Common (1–10%) | Mild | Stay hydrated, avoid high-fat meals | Usually intermittent, not persistent |
| Constipation | Common (1–10%) | Mild | Increase fiber and water intake | May persist at therapeutic dose |
| Fatigue | Common (1–10%) | Mild | Maintain adequate caloric intake, ensure protein sufficiency | Usually resolves as body adapts |
| Injection site reactions | Common (1–10%) | Mild | Rotate injection sites, use proper technique | Typically resolves with site rotation |
| Pancreatitis | Rare (<0.1%) | Serious | Discontinue immediately, seek medical attention | Requires medical management |
| Thyroid C-cell effects | Animal data only | Theoretical | Contraindicated with personal/family history of MTC | Precautionary contraindication |
| Side Effect | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Nausea | High (30–44%) | High (25–45%) | High (47–58%) |
| Vomiting | Moderate (14–24%) | Moderate (8–25%) | High (20–35%) |
| Diarrhea | Moderate (12–30%) | Moderate (13–30%) | Moderate (15–25%) |
| Constipation | Moderate (11–24%) | Moderate (11–17%) | Moderate (10–15%) |
| Serious events | Rare | Rare | Rare |
Data from Phase 2/3 clinical trials at therapeutic doses. Rates vary by dose level and titration speed.
Extending each dose step from 4 to 6–8 weeks is the single most effective way to reduce GI side effects. There is no clinical benefit to rushing titration.
Injecting in the evening means peak nausea occurs during sleep. Many researchers report this eliminates daytime nausea entirely.
Avoid high-fat, spicy, and heavily processed foods during the titration phase. Smaller, more frequent meals reduce gastric distension and nausea.
GLP-1 agonists slow gastric emptying. Adequate hydration (2–3L/day) reduces constipation and supports tolerability.
Reduced appetite can lead to inadequate protein intake, causing fatigue and muscle loss. Target 1.2–1.6g/kg of body weight daily.
Irregular dosing causes repeated re-exposure to peak side effects. Consistent weekly dosing allows the body to maintain stable receptor adaptation.
The most common GLP-1 side effects are gastrointestinal: nausea (10–58% depending on compound and dose), vomiting (8–35%), diarrhea (12–30%), and constipation (10–24%). These are most pronounced during dose escalation and typically resolve within 8–12 weeks as the body adapts.
Yes, most GLP-1 side effects are transient. Nausea and vomiting are most common during the titration phase (weeks 1–8) and typically resolve by week 12. Constipation may persist at therapeutic doses. Serious side effects (pancreatitis, thyroid effects) are rare and require immediate discontinuation.
Semaglutide generally has the mildest GI side effect profile among the three GLP-1 agents. Tirzepatide has similar GI effects. Retatrutide has the highest rates of nausea and vomiting (47–58% nausea at therapeutic doses) due to the additional glucagon receptor agonism. All three share the same class-level side effect profile.
Key strategies: slow titration (extending each dose step to 6–8 weeks instead of 4), taking the injection in the evening so nausea occurs during sleep, eating smaller and more frequent meals, avoiding high-fat meals, staying hydrated, and maintaining adequate protein intake to prevent fatigue from caloric restriction.
Semaglutide has the longest safety record with cardiovascular outcome trials showing benefit in high-risk populations. Tirzepatide has 2+ years of Phase 3 data. Retatrutide has 48-week Phase 2 data. All three are generally well-tolerated long-term, with the main ongoing consideration being GI effects and the theoretical thyroid C-cell risk (which has not been observed in human trials).
Purgo Labs carries pharmaceutical-grade semaglutide, tirzepatide, and retatrutide with third-party COAs. Use code HEALTH for 15% off.
Shop Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.